Interesting Stats | Contact Us | Free Content  
 

ETHEX Corporation Voluntarily Recalls Three Lots of Dextroamphetamine Sulfate 5mg Tablets Due to the Potential for Oversized Tablets

Subscribe to our Drugs Recalls RSS Feed
Date of Recall:
Wednesday, October 15th, 2008

Recall Details:

St. Louis, MO – October 15, 2008 – ETHEX Corporation announced today that it has voluntarily recalled three specific lots (77946, 81141 and 81142) of Dextroamphetamine Sulfate 5 mg tablets, as a precaution, due to the possible presence of oversized tablets. Oversized tablets may contain as much as about twice the labeled amount of the active ingredient. The recalled lots were distributed by ETHEX Corporation under an "ETHEX" label between January 2007 and May 2008. The 5 mg product is an orange round tablet debossed with "ETHEX" and "311" on one side.

If someone were to take a higher than expected dose of Dextroamphetamine Sulfate, then the risk of adverse effects known to be associated with the drug such as tachycardia, hypertension, tremors, decreased appetite, headache, insomnia, dizziness, blurred vision, stomach upset, and dry mouth may be increased.

No report of any oversized Dextroamphetamine Sulfate tablets has been received by ETHEX from any wholesaler, retailer, consumer or caregiver, and ETHEX has not received any report of unexpected side effects or injury related to this product.

ETHEX Corporation is conducting this precautionary, voluntary recall because it found a small number of oversized tablets in lots which had not yet been distributed. These oversized tablets were removed before the lots were distributed.

Please be aware that there are multiple companies in the United States producing and marketing generic versions of Dextroamphetamine Sulfate 5 mg tablets and consumers and their caregivers are encouraged to check their prescriptions to determine the source of their tablets.

Any customer inquiries related to this action should be addressed to ETHEX Customer Service at 1-800-321-1705, or fax to ETHEX Customer Service at 314-646-3751 or sent via email to: customer-service@ethex.com with representatives available Monday through Friday, 8 am to 5 pm CST.

ETHEX Corporation has initiated recall notifications to wholesalers and retailers nationwide who have received any inventory of the recalled lots of this product with instructions for returning the recalled product and, if they have not already done so, they are urged to contact ETHEX as provided above regarding procedures for returning the recalled product. Consumers and their caregivers should not use any Dextroamphetamine Sulfate tablets that appear to be oversized. If consumers have any questions about the recall, they should call the telephone number above, their physician, their pharmacist or other health care provider.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA).

Any adverse reactions experienced with the use of this product, and/or quality problems may also be reported to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by Fax at 1-800-FDA-0178, by mail at MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at www.fda.gov/medwatch.

  User Comments  
There are currently no comments for this recall. Be the first to add a comment!
Click here to add a comment about this recall.
  Advertisements  
  Topical Videos  
All video content powered by YouTube.

A humerous look at Chinese product recalls Read More...
  Interesting Stats  
Most Consumer Recalls
by Country
  Popular Searches  
  Related News  

Report: Toyota resisted Sienna recall in 2008
Instead of issuing a recall under the US Safety Act, Toyota sent letters to owners of 196222 Sienna vans offering to replace struts on the liftgates as part ...
Local doctors discard H1N1 flu vaccine due to second recall
"This is absurd," said Dr. Harry Romanowitz, the practice's medical director, as he carried stacks of vaccine boxes to dump into a medical waste box. ...
FDA recommends recall of Avandia diabetes drug due to heart-related deaths
... diabetes drug development, said, “We remain very confident in the safety and of course in the efficacy of Avandia as an important diabetic medicine. ...